

Express Mail Label: EV 392154984 US  
Date of Deposit: June 3, 2004



Page 1 of 2  
Attorney Docket No.: 18217-519

Please type a plus sign (+) in this box



Modified Form 1449/PTO				Application Number		10/790,662	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)				Filing Date		March 1, 2004	
				First Named Inventor		Chaplin	
				Group Art Unit		Not Yet Assigned 1614	
				Examiner Name		Not Yet Assigned TIMOTHY E. BOSTON	
				Attorney Docket Number		18217-519	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
TJB	A1	5,079,257	01/07/92	Speckamp, et al.	514	312	
TJB	A2	5,409,953	04/25/95	Pettit, et al.	514	484	
TJB	A3	5,430,062	07/04/95	Cushman, et al.	514	646	
TJB	A4	5,525,832	06/11/98	Obsumi, et al.	514	646	
TJB	A5	5,567,786	10/22/96	Tseng, et al.	526	264	
TJB	A6	5,674,306	10/07/97	Hatanaka, et al.	514	628	
TJB	A7	6,423,753 B1	07/23/02	Dougherty	514	719	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No	
TJB	B1	WO 92/16486	Aston Molecules Limited	10/01/92			
TJB	B2	WO 99/02166	Angiogene Pharmaceuticals Ltd.	01/21/99			
TJB	B3	WO 00/40529	Angiogene Pharmaceuticals, Ltd.	07/13/00			
TJB	B4	WO 00/68528	Sill Biomedical Corporation	11/09/00			
TJB	B5	WO 01/32210 A2	Pharmacyclics, Inc.; Univ. of Texas System	05/10/01			
TJB	B6	WO 01/81355 A1	Arizona Board of Regents	11/01/01			
TJB	B7	WO 02/02110 A1	Cancer Research Ventures Ltd.	01/10/02			
TJB	B8	WO 02/04434 A1	Angiogene Pharmaceuticals Ltd.	01/17/02			
TJB	B9	WO 02/08213 A1	Angiogene Pharmaceuticals Ltd.	01/31/02			
TJB	B10	WO 02/12227 A2	AstraZeneca AB	02/14/02			
TJB	B11	WO 02/14329 A1	Angiogene Pharmaceuticals Ltd.	02/21/02			
TJB	B12	WO 02/49994 A2	Cancer Research Ventures Ltd.	08/27/02			
TJB	B13	WO 02/50007 A2	Cancer Research Ventures Ltd.	06/27/02			
TJB	B14	WO 03/035008 A2	OXIGENE, Inc.	05/01/03			
TJB	B15	WO 03/040077 A1	Paterson Institute for Cancer Res.; The Univ. of Manchester Institute of Science and Technology	05/15/03			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
TJB	C1	Amaro, et al., "Metabolic activation of PCBs to Quinones: reactivity toward nitrogen and sulfur nucleophiles and influence of superoxide dismutase", <i>Chem. Res. Toxicol.</i> , 9:623-629 (1996).					
TJB	C2	Begleiter, A., "Clinical applications of quinone-containing alkylating agents", <i>Frontiers in Biosci.</i> , 5:e153-171 (2000).					
TJB	C3	Bolton, J. L., "Quinoids, quinoid radicals, and phenoxy radicals formed from estrogens and antiestrogens", <i>Toxicology</i> , 177:55-65 (2002).					

*Timothy E. Boston*

11/1/07

723	C4	Bui, et al., "Direct biocatalytic synthesis of functionalized catechols: a green alternative to traditional methods with high effective mass yield", <i>Green Chem.</i> , 2:263-265 (2000).
723	C5	Bui, et al., "Direct biooxidation of arenas to corresponding catechols with E.coli JM109 (pDTG602). Application to synthesis of combretastatins A-1 and B-1", <i>Tetrahedron Lett.</i> , 43:2839-2841 (2002).
723	C6	Fan, et al., "4-hydroxylated metabolites of antiestrogens, tamoxifen and toremifene are metabolized to unusually stable quinone methides", <i>Chem. Res. Toxicol.</i> , 13(1):45-52 (2000).
723	C7	Falg, et al., "Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones", <i>Structure</i> , 9(8):659-667 (2001).
723	C8	Flowers-Geary, et al., "Cytotoxicity and mutagenicity of polycyclic aromatic hydrocarbon ortho-quinones produced by dihydrodiol dehydrogenase", <i>Chem. Biol. Interact.</i> , 99(1-3):55-72 (1996).
723	C9	Gastpar, et al., "Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization", <i>J. Med. Chem.</i> , 41: 4965-4972 (1998).
723	C10	Gutierrez, P. L., "The metabolism of quinone-containing alkylating agents: free radical production and measurement", <i>Frontiers in Biosci.</i> , 5:d629-638 (2000).
723	C11	Gutierrez, P. L., "The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: a review", <i>Free Radic. Biol. Med.</i> , 29(3-4):263-275 (2000).
723	C12	Ham, et al., "Mechanism of cell cycle arrest by menadione", <i>Bull. Korean Chem. Soc.</i> , 21(12):1173-1174 (2000).
723	C13	Hill, et al., "Preclinical evaluation of the antitumor activity of the novel vascular targeting agent Oxi 4503", <i>Anticancer Res.</i> , 22:1453-1458 (2002).
723	C14	Holwell, et al., "Anti-tumor and Anti-vascular effects of the novel tubulin-binding agent Combretastatin A-1 Phosphate", <i>Anticancer Res.</i> , 22:3933-3940 (2002).
723	C15	Holwell, et al., "Combretastatin A-1 Phosphate a novel tubulin binding agent with <i>in vivo</i> anti-vascular effects in experimental tumors", <i>Anticancer Res.</i> , 22:707-712 (2002).
723	C16	Li, et al., "Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer", <i>Expert Opin. Ther. Patents</i> , 12(11):1663-1702 (2002).
723	C17	Pang, et al., "Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry", <i>J. Mass Spectrom.</i> , 36:771-781 (2001).
723	C18	Pettit, et al., "Antineoplastic agents 429: Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs", <i>Anti-Cancer Drug Design</i> , 15:203-26 (2000).
723	C19	Pettit, et al., "Antineoplastic agents 440: Asymmetric synthesis and evaluation of the Combretastatin A-1 probes (1S,2S)- and (1R,2R)-1,2-dihydroxy-1-(2',3'-dihydroxy-4'-methoxyphenyl)-2-(3', 4',5'-trimethoxyphenyl)-ethane", <i>J. Nat. Prod.</i> , 63:969-674 (2000).
723	C20	Pettit, et al., "Antineoplastic agents 389: New syntheses of the combretastatin A-4 prodrug", <i>Anti-Cancer Drug Design</i> , 13:183-191 (1998).
723	C21	Singh, et al., "Isolation, structure, and synthesis of combretastatin C-1", <i>J. Org. Chem.</i> , 54:4105-4114 (1989).
723	C22	Sridhar, et al., "Amino acid adducts of PAH o-quinones: model studies with naphthalene-1,2-dione", <i>Tetrahedron</i> , 57:407-412 (2001).
723	C23	Wardman, P., "Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia", <i>Curr. Med. Chem.</i> , 8(7): 739-761 (2001).
723	C24	Workman, P., "Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase", <i>Oncol. Res.</i> , 6(10-11):461-475 (1994).
723	C25	Yao, et al., "Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones", <i>Chem. Res. Toxicol.</i> , 14(12):1643-1653 (2001).
723	C26	Zhang, et al., "Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone", <i>Chem. Res. Toxicol.</i> , 13(1):53-62 (2000).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Timothy E. Betton	Date Considered	11/1/07
-----------------------	-------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.